Nevio Cimolai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Nevio Cimolai has a total of 2 co-authors. Here are the top co-authors by number of shared publications:
J.E. Carter
Division of Medical Microbiology, Departments of Pathology and Pediatrics, British Columbia's Children's Hospital, Vancouver V6H 3V4, Canada
1 shared publicationTomas L Cimolai
1 shared publication
Latest Publications
- 11 July 2025
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 44 (10) , 2295-2302
Community-acquired staphylococcal scalded skin syndrome in an immunocompetent adult
Staphylococcal scalded skin syndrome is an exfoliative skin eruption associated with specific exotoxin-producing strains of Staphylococcus aureus. Affliction of adults is considerably rare, and most such patients have pre-disposing co-morbidities. A unique such infection of an immunocompetent adult without risk factors is detailed. Current concepts of disease process and treatment are highlighted for staphylococcal scalded skin syndrome among adults.
- 11 July 2025
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 44 (10) , 2295-2302
Community-acquired staphylococcal scalded skin syndrome in an immunocompetent adult
Staphylococcal scalded skin syndrome is an exfoliative skin eruption associated with specific exotoxin-producing strains of Staphylococcus aureus. Affliction of adults is considerably rare, and most such patients have pre-disposing co-morbidities. A unique such infection of an immunocompetent adult without risk factors is detailed. Current concepts of disease process and treatment are highlighted for staphylococcal scalded skin syndrome among adults.
- 9 April 2024
- Published by Springer Nature in SN Comprehensive Clinical Medicine
- Vol. 6 (1) , 1-15
Psychosocial Aspects of Maternal Reproductive Health in the Era of COVID-19
- 9 April 2024
- Published by Springer Nature in SN Comprehensive Clinical Medicine
- Vol. 6 (1) , 1-15
Psychosocial Aspects of Maternal Reproductive Health in the Era of COVID-19
- 2 April 2024
- Published by Wiley in Acta Paediatrica
- Vol. 113 (7) , 1732-1733
Admission diagnostics for SARS‐CoV‐2 and other respiratory viruses
- 2 April 2024
- Published by Wiley in Acta Paediatrica
- Vol. 113 (7) , 1732-1733
Admission diagnostics for SARS‐CoV‐2 and other respiratory viruses
- Open Access
- 15 January 2024
- Published by Korean Pediatric Society in Clinical and Experimental Pediatrics
- Vol. 67 (1) , 1-16
COVID-19 among infants: key clinical features and remaining controversies
Infants aged <1 year represent a seemingly more susceptible pediatric subset for infections. Despite this, coronavirus disease 2019 (COVID-19) infection has not been proven as more serious in this age group (outside the very early neonatal period) than in others. Indeed, a considerable number of asymptomatic infections have been recorded, and the symptoms and morbidity associated with COVID- 19 differ minimally from those of other respiratory viral infections. Whether due to an abundance of caution or truly reduced susceptibility, infections in infants have not raised the same profile as those in other age groups. In addition to direct severe acute respiratory syndrome coronavirus 2 diagnostic tests, laboratory markers that differentiate COVID-19 from other viral infections lack specificity in infants. Gastrointestinal presentations are common, and the neurological complications of infection mirror those of other respiratory viral infections. There have been relatively few reports of infant deaths. Under appropriate precautions, breastfeeding in the context of maternal infections has been associated with tangible but infrequent complications. Vaccination during pregnancy provides protection against infection in infants, at least in the early months of life. Multi-inflammatory syndrome in children and multi-inflammatory syndrome in neonates are commonly cited as variants of COVID-19; however, their clinical definitions remain controversial. Similarly, reliable definitions of long COVID in the infant group are controversial. This narrative review examines the key clinical and laboratory features of COVID-19 in infants and identifies several areas of science awaiting further clarification.
- 15 January 2024
- Published by Korean Pediatric Society in Clinical and Experimental Pediatrics
- Vol. 67 (1) , 1-16
Open AccessCOVID-19 among infants: key clinical features and remaining controversies
Infants aged <1 year represent a seemingly more susceptible pediatric subset for infections. Despite this, coronavirus disease 2019 (COVID-19) infection has not been proven as more serious in this age group (outside the very early neonatal period) than in others. Indeed, a considerable number of asymptomatic infections have been recorded, and the symptoms and morbidity associated with COVID- 19 differ minimally from those of other respiratory viral infections. Whether due to an abundance of caution or truly reduced susceptibility, infections in infants have not raised the same profile as those in other age groups. In addition to direct severe acute respiratory syndrome coronavirus 2 diagnostic tests, laboratory markers that differentiate COVID-19 from other viral infections lack specificity in infants. Gastrointestinal presentations are common, and the neurological complications of infection mirror those of other respiratory viral infections. There have been relatively few reports of infant deaths. Under appropriate precautions, breastfeeding in the context of maternal infections has been associated with tangible but infrequent complications. Vaccination during pregnancy provides protection against infection in infants, at least in the early months of life. Multi-inflammatory syndrome in children and multi-inflammatory syndrome in neonates are commonly cited as variants of COVID-19; however, their clinical definitions remain controversial. Similarly, reliable definitions of long COVID in the infant group are controversial. This narrative review examines the key clinical and laboratory features of COVID-19 in infants and identifies several areas of science awaiting further clarification.
- 21 September 2023
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 182 (12) , 5717-5718
Continuing difficulties in distinguishing COVID-19 MIS-C from other disease entities
- 21 September 2023
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 182 (12) , 5717-5718
Continuing difficulties in distinguishing COVID-19 MIS-C from other disease entities
- 13 July 2023
- Published by Springer Nature in Hypertension Research
- Vol. 46 (9) , 2247-2248
Microvascular hypertensive disease, Long COVID, and end-organ pathology
- 13 July 2023
- Published by Springer Nature in Hypertension Research
- Vol. 46 (9) , 2247-2248
Microvascular hypertensive disease, Long COVID, and end-organ pathology
- 18 July 2022
- Published by Wiley in Journal of Medical Virology
- Vol. 94 (10) , 4654-4668
Disinfection and decontamination in the context of SARS‐CoV‐2‐specific data
Given the high transmissibility of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) as witnessed early in the coronavirus disease 2019 (COVID‐19) pandemic, concerns arose with the existing methods for virus disinfection and decontamination. The need for SARS‐CoV‐2‐specific data stimulated considerable research in this regard. Overall, SARS‐CoV‐2 is practically and equally susceptible to approaches for disinfection and decontamination that have been previously found for other human or animal coronaviruses. The latter have included techniques utilizing temperature modulation, pH extremes, irradiation, and chemical treatments. These physicochemical methods are a necessary adjunct to other prevention strategies, given the environmental and patient surface ubiquity of the virus. Classic studies of disinfection have also allowed for extrapolation to the eradication of the virus on human mucosal surfaces by some chemical means. Despite considerable laboratory study, practical field assessments are generally lacking and need to be encouraged to confirm the correlation of interventions with viral eradication and infection prevention. Transparency in the constitution and use of any method or chemical is also essential to furthering practical applications.
- 18 July 2022
- Published by Wiley in Journal of Medical Virology
- Vol. 94 (10) , 4654-4668
Disinfection and decontamination in the context of SARS‐CoV‐2‐specific data
Given the high transmissibility of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) as witnessed early in the coronavirus disease 2019 (COVID‐19) pandemic, concerns arose with the existing methods for virus disinfection and decontamination. The need for SARS‐CoV‐2‐specific data stimulated considerable research in this regard. Overall, SARS‐CoV‐2 is practically and equally susceptible to approaches for disinfection and decontamination that have been previously found for other human or animal coronaviruses. The latter have included techniques utilizing temperature modulation, pH extremes, irradiation, and chemical treatments. These physicochemical methods are a necessary adjunct to other prevention strategies, given the environmental and patient surface ubiquity of the virus. Classic studies of disinfection have also allowed for extrapolation to the eradication of the virus on human mucosal surfaces by some chemical means. Despite considerable laboratory study, practical field assessments are generally lacking and need to be encouraged to confirm the correlation of interventions with viral eradication and infection prevention. Transparency in the constitution and use of any method or chemical is also essential to furthering practical applications.
- 1 June 2022
- Published by Wiley in Epileptic Disorders
- Vol. 24 (3) , 628-629
Epilepsy and clinically latent cerebrovascular disease
- 1 June 2022
- Published by Wiley in Epileptic Disorders
- Vol. 24 (3) , 628-629
Epilepsy and clinically latent cerebrovascular disease
- 22 March 2022
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 226 (4) , 751-752
Autoantibodies and COVID-19: Rediscovering Nonspecific Polyclonal B-Cell Activation?
- 22 March 2022
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 226 (4) , 751-752
Autoantibodies and COVID-19: Rediscovering Nonspecific Polyclonal B-Cell Activation?